NCT02434445View on ClinicalTrials.gov

Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients

RecruitingOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

June 1, 2012

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions

Hepatorenal Syndrome

Trial Locations (1)

Unknown

RECRUITING

Queen Mary Hospital, Hong Kong, Hong Kong

All Listed Sponsors

collaborator

The Hong Kong Society of Nephrology

OTHER

lead

The University of Hong Kong

OTHER

NCT02434445 - Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients | Biotech Hunter | Biotech Hunter